Enzychem Lifesciences Corporation (183490.KQ)
KRW 1329.0
(-2.71%)
KRW 1329.0
(-2.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 211.54 Billion KRW | -14.55% |
| 2022 | 247.55 Billion KRW | 86.01% |
| 2021 | 133.08 Billion KRW | 7.5% |
| 2020 | 123.8 Billion KRW | 45.66% |
| 2019 | 84.99 Billion KRW | 26.77% |
| 2018 | 67.04 Billion KRW | 82.17% |
| 2017 | 36.8 Billion KRW | 0.37% |
| 2016 | 36.66 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 208.4 Billion KRW | -1.49% |
| 2024 Q2 | 195.13 Billion KRW | -6.36% |
| 2023 Q1 | 219.99 Billion KRW | -11.13% |
| 2023 FY | 211.54 Billion KRW | -14.55% |
| 2023 Q3 | 216.22 Billion KRW | 0.86% |
| 2023 Q2 | 214.37 Billion KRW | -2.56% |
| 2023 Q4 | 211.54 Billion KRW | -2.16% |
| 2022 Q2 | 280.77 Billion KRW | -0.35% |
| 2022 Q1 | 281.75 Billion KRW | 111.71% |
| 2022 Q4 | 247.55 Billion KRW | -10.01% |
| 2022 FY | 247.55 Billion KRW | 86.01% |
| 2022 Q3 | 275.09 Billion KRW | -2.02% |
| 2021 Q4 | 133.08 Billion KRW | -4.96% |
| 2021 Q2 | 144.71 Billion KRW | -3.78% |
| 2021 Q3 | 140.03 Billion KRW | -3.23% |
| 2021 Q1 | 150.39 Billion KRW | 21.48% |
| 2021 FY | 133.08 Billion KRW | 7.5% |
| 2020 Q4 | 123.8 Billion KRW | 48.05% |
| 2020 FY | 123.8 Billion KRW | 45.66% |
| 2020 Q1 | 82.17 Billion KRW | -3.31% |
| 2020 Q3 | 83.62 Billion KRW | -0.63% |
| 2020 Q2 | 84.15 Billion KRW | 2.41% |
| 2019 Q4 | 84.99 Billion KRW | -6.6% |
| 2019 FY | 84.99 Billion KRW | 26.77% |
| 2019 Q1 | 69.93 Billion KRW | 4.3% |
| 2019 Q3 | 90.99 Billion KRW | -1.42% |
| 2019 Q2 | 92.3 Billion KRW | 32.0% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | 67.04 Billion KRW | 82.17% |
| 2018 Q2 | 74.57 Billion KRW | 0.0% |
| 2018 Q3 | 71.4 Billion KRW | -4.26% |
| 2018 Q4 | 67.04 Billion KRW | -6.1% |
| 2017 FY | 36.8 Billion KRW | 0.37% |
| 2017 Q4 | 36.8 Billion KRW | 0.0% |
| 2016 FY | 36.66 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | -49.659% |
| CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | -13.216% |
| Celltrion Pharm, Inc. | 641.64 Billion KRW | 67.031% |
| Huons Global Co., Ltd. | 1317.96 Billion KRW | 83.949% |
| DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 74.802% |
| Humedix Co., Ltd. | 219.97 Billion KRW | 3.833% |
| Boditech Med Inc. | 227.9 Billion KRW | 7.177% |
| EuBiologics Co., Ltd. | 172.64 Billion KRW | -22.534% |
| FutureChem Co.,Ltd | 72.83 Billion KRW | -190.452% |
| Huons Co., Ltd. | 537.28 Billion KRW | 60.627% |
| BNC Korea Co., Ltd. | 236.15 Billion KRW | 10.42% |
| AptaBio Therapeutics Inc. | 92.51 Billion KRW | -128.651% |